Peptonic Medical signs agreement for distribution of self-test for bacterial vaginosis with exclusivity in Sweden, Norway and Denmark

  • -

Peptonic Medical AB (publ) (‘Peptonic’ or ‘the company’) announces today that they have signed an agreement with Common Sense, Ltd. (Common Sense) on the distribution of a self-diagnostic test for bacterial vaginosis. The distribution rights apply to 28 countries, of which exclusive rights apply to Sweden, Norway and Denmark. Among the non-exclusive countries are e.g. England, Germany, France, Spain, Italy and Australia. Peptonic will launch the self-test under the VagiVital® brand.

The self-tests have been developed by Common Sense and are sold today in the USA and in a number of countries in Europe e.g. England, Italy and the Netherlands. In clinical studies the self-test has shown a sensitivity of 91.8% and a specificity of 92.8%. The read-out of the self-test is given in a few seconds and no samples need to be sent for laboratory analyses.

– This is an exciting technology that we now have the opportunity to offer our customers. Many women who are bothered by vaginal discharges with unpleasant smell are reluctant to go to the doctor for consultation. Then this self-test is a flexible alternative that gives a quick first answer, says Johan Inborr, CEO of Peptonic. Of course, we also want to be able to offer a safe and effective treatment of bacterial vaginosis in the future.

The launch of the self-tests is planned for the third quarter of 2021.

For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
E-mail:  johan.inborr@peptonicmedical.se

This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 1st December, 2020.


About Bacterial Vaginos

Bacterial vaginosis is the most common cause of troublesome / foul-smelling discharge in women of childbearing age. Normally, the vagina is colonized by lactobacilli that maintain a low pH and thus some protection against infections. In bacterial vaginosis, the lactobacilli are displaced by other bacteria, often anaerobes, which cause the release of foul-smelling amines. An elevated pH value contributes to the process.

Bacterial vaginosis increases the risk of premature child birth and can also contribute to intra-abdominal infections in connection with vaginal surgery (source: Internetmedicin.se). 

An estimated 15-30% of all women suffer from bacterial vaginosis. 

Bacterial vaginosis is primarily treated with antibiotics.

About Common Sense Ltd.

Common Sense Ltd. was established in 1999 by a group of scientists wishing to invent and develop innovative products in the field of women’s healthcare. 

The company develops and manufactures Women’s Health Care diagnostic tests aimed at both the OTC market as well as the professional healthcare market. Product lines include test for identifying vaginal infections and tests for detection of Amniotic Fluid Leaks.

Common Sense products have been successfully launched in North America under both Private Label as well as leading Women’s Healthcare Brands (2014) and in Europe (2015). Expansion into other major world markets including Asian and Latin American markets started 2018. Common Sense products are available in major retail and pharmacy outlets throughout the USA and in leading pharmacies in Europe.

About Peptonic Medical 

Peptonic Medical AB (publ) is an innovative biomedical company that conducts research on and development of drugs and medical devices in the field of women’s health. Our vision is to offer safe and effective treatments for women-specific diseases and medical conditions. Peptonic Medical launched VagiVital® in July 2018. This is a hormone-free product for the treatment of vaginal atrophy and vaginal dryness.

The company’s development program also includes Vagitocin® – a product that contains oxytocin for the treatment of vaginal atrophy. The development of Vagitocin® has been put on hold pending new information regarding the mechanism of action of oxytocin in this indication.

The company was founded in 2009 and the share has been traded since 2014 on Spotlight (www.spotlightstockmarket.se, short code: PMED) in Stockholm.

Since August 2020, Lune Group Oy Ltd. is a wholly owned subsidiary of the Peptonic Medical Group. Lune Group Oy Ltd.was founded in 2005 by Heli Kurjanen and has earned its place as a top global menstrual cup company through its continued focus on quality, safety, sustainability and inclusivity. Lunetteâ Menstrual Cups are an alternative to disposable period products lasting for several years. The company has resellers in 50 countries and sells Lunetteâ products to over 100 countries via its online store. In the USA, Lune Group has a subsidiary (Lune North America Inc.) Lunetteâ Menstrual Cups are designed, manufactured and packaged in Finland. You can get more information about Lunetteâ by visiting https://se.lunette.com/.